![Shannon Westin: Overall survival is improved in all comers in the RUBY study of Immunotherapy and chemotherapy in advanced/recurrent Endometrial Cancer](https://oncodaily.com/pub/uploads/2024/03/IMG_1794.jpeg)
Photo taken from Shannon Westin/X
Mar 26, 2024, 09:45
Shannon Westin: Overall survival is improved in all comers in the RUBY study of Immunotherapy and chemotherapy in advanced/recurrent Endometrial Cancer
Shannon Westin, Professor at Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, shared a post on X/Twitter:
“Overall survival is improved in all comers in the RUBY study of Immunotherapy and chemotherapy in advanced/recurrent Endometrial Cancer – 31% reduction in risk of death consistent with 16 month improvement!!!”
Source: Shannon Westin/X